{'fraction_non_alphanumeric': 0.025815217391304348, 'fraction_numerical': 0.0, 'mean_word_length': 5.952830188679245, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Treatment options for patients with multiple sclerosis who have a suboptimal response to interferon‐β therapy

Although the first‐line disease‐modifying therapies (DMTs) interferon beta and glatiramer acetate have a favourable benefit‐to‐risk profile, they are only partially effective for treating relapsing–remitting multiple sclerosis (RRMS). The optimization of treatment in patients who do not show a maximum response to first‐line therapy is critical for achieving the best long‐term outcomes. Treatment strategies for patients with a suboptimal response include switching to another first‐line DMT or a second‐line DMT. Natalizumab and fingolimod are approved for RRMS with high disease activity in the European Union and Canada.